Taldefgrobep Alfa

Summary

Taldefgrobep Alfa (CHEMBL4297914) is a phase-3 clinical-stage protein; indicated across 4 conditions including spinal muscular atrophy and duchenne muscular dystrophy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297914
Name	Taldefgrobep Alfa
Type	Protein
Max phase	3

Also known as: Bms-986089, BMS-986089, RO-7239361, Ro7239361, RO7239361, Taldefgrobep alfa, Talditercept alfa, TALDEFGROBEP ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
spinal muscular atrophy	3	MONDO:0001516	EFO:0008525
Duchenne muscular dystrophy	2	MONDO:0010679	MONDO:0010679
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	2
PHASE2/PHASE3	1
PHASE3	1
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05337553	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT03039686	PHASE2/PHASE3	COMPLETED	Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
NCT07281495	PHASE2	ACTIVE_NOT_RECRUITING	Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT02515669	PHASE1/PHASE2	TERMINATED	Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD
NCT02145234	PHASE1	COMPLETED	Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects
NCT03100630	PHASE1	COMPLETED	Compare Bioavailability of RO7239361 After Subcutaneous Injection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).